Table 2.
Overall and age-stratified PAH drug therapy utilization patterns in Ontario between April 1, 2011, and March 31, 2012.
| PAH drug therapy | Overall N = 301∗ |
Age < 65 N = 152 |
Age ≥ 65 N = 149 |
p value Age < 65 versus age ≥ 65 |
|---|---|---|---|---|
| N (%) | N (%) | N (%) | ||
| Overall single therapy | 232 (77.1%) | 118 (77.6%) | 114 (76.5%) | 0.817 |
| Overall combination therapy | 69 (22.9%) | 34 (22.4%) | 35 (23.5%) | 0.817 |
| Types of single therapy | ||||
| PDE5 inhibitors | 66 (28.4%) | 23–28 (19–24%)∗ | 40–45 (35–39%) | 0.013 |
| ERA | 140 (60.3%) | 65–70 (55–59%) | 70–75 (61–66%) | 0.389 |
| Prostanoids | 26 (11.2%) | 21–26 (20–22%) | ≤5 (0–4%) | <0.001 |
| Types of combination therapy | ||||
| PDE5 inhibitors + ERA | 62 (89.9%) | 28–33 (82–97%) | 29–34 (83–97%) | 0.661 |
∗Ranges provided for privacy reasons to avoid reidentification of small cell sizes.
Note: 25 out of 326 patients did not have a subsequent PAH prescription over the follow-up period, despite having a past PAH prescription, and therefore are excluded from this analysis.